Literature DB >> 23317227

Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells.

Wei Song1, Rui Jiang, Chun-Ming Zhao.   

Abstract

Gastric carcinoma is a leading cause of cancer death in the world and multi-drug resistance (MDR) is an essential aspect of gastric carcinoma chemotherapy failure. Recent studies have shown that integrin-linked kinase (ILK) is involved in metastasis of human tumors, expression silencing of ILK inhibiting the metastasis of several types of cultured human cancer cells. However, the role and potential mechanism of ILK to reverse the multi- drug resistance in human gastric carcinoma is not fully clear. In this report, we focused on roles of expression silencing of ILK in multi-drug resistance reversal of human gastric carcinoma SGC7901/DDP cells, including increased drug sensitivity to cisplatin, cell apoptosis rates, and intracellular accumulation of Rhodamine-123, and decreased mRNA and protein expression of multi-drug resistance gene (MDR1), multi-drug resistance- associated protein (MRP1), excision repair cross-complementing gene 1 (ERCC1), glutathione S-transferase -π (GST-π) and RhoE, and transcriptional activation of AP-1 and NF-κB in ILK silenced SGC7901/DDP cells. We also found that there was a decreased level of p-Akt and p-ERK. The results indicated that ILK might be used as a potential therapeutic strategy to combat multi-drug resistance through blocking PI3K-Akt and MAPK-ERK pathways in human gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23317227     DOI: 10.7314/apjcp.2012.13.11.5619

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

Review 1.  Pathophysiological Functions of Rnd3/RhoE.

Authors:  Wei Jie; Kelsey C Andrade; Xi Lin; Xiangsheng Yang; Xiaojing Yue; Jiang Chang
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

2.  ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance.

Authors:  Dimitrios Tsoumas; Sofia Nikou; Efstathia Giannopoulou; Spyridon Champeris Tsaniras; Chaido Sirinian; Ioannis Maroulis; Stavros Taraviras; Vassiliki Zolota; Haralabos P Kalofonos; Vasiliki Bravou
Journal:  Cancer Genomics Proteomics       Date:  2018 Mar-Apr       Impact factor: 4.069

3.  Prognostic and clinic-pathological significances of HOXB8, ILK and FAT4 expression in colorectal cancer.

Authors:  Abdulwahab A Abuderman; Ola A Harb; Loay M Gertallah
Journal:  Contemp Oncol (Pozn)       Date:  2020-10-30

4.  Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.

Authors:  Luodan Zhao; Yuexin Ren; Haikuo Tang; Wei Wang; Qianting He; Jingjing Sun; Xiaofeng Zhou; Anxun Wang
Journal:  Oncotarget       Date:  2015-12-29

5.  RNA silencing of integrin-linked kinase increases the sensitivity of the A549 lung cancer cell line to cisplatin and promotes its apoptosis.

Authors:  Xiaozhen Zhao; Zhenye Xu; Zhongqi Wang; Zhonghua Wu; Yabin Gong; Lijuan Zhou; Yi Xiang
Journal:  Mol Med Rep       Date:  2015-03-11       Impact factor: 2.952

Review 6.  Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?

Authors:  Leonardo Marques da Fonseca; Vanessa Amil da Silva; Leonardo Freire-de-Lima; José Osvaldo Previato; Lucia Mendonça-Previato; Márcia Alves Marques Capella
Journal:  Front Oncol       Date:  2016-06-22       Impact factor: 6.244

Review 7.  Curcumin, a Multifaceted Hormetic Agent, Mediates an Intricate Crosstalk between Mitochondrial Turnover, Autophagy, and Apoptosis.

Authors:  Nathan Earl Rainey; Aoula Moustapha; Patrice Xavier Petit
Journal:  Oxid Med Cell Longev       Date:  2020-07-18       Impact factor: 6.543

8.  [The effect and mechanism of vinorelbine on cisplatin resistance of human lung cancer cell line A549/DDP].

Authors:  Chunsheng Qi; Sen Gao; Huiqiang Li; Weizhen Gao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-02

9.  Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer.

Authors:  Jeyshka M Reyes-González; Blanca I Quiñones-Díaz; Yasmarie Santana; Perla M Báez-Vega; Daniel Soto; Fatima Valiyeva; María J Marcos-Martínez; Ricardo J Fernández-de Thomas; Pablo E Vivas-Mejía
Journal:  Cancers (Basel)       Date:  2020-04-04       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.